TRIM33 and cancer: This hypothesis is consistent with data from other next-generation sequencing and whole-exome sequencing experiments in cancer patients, which show that the formation of TIF1γ neoantigens due to somatic mutations of the TRIM33 gene could trigger the production of anti-TIF1γ antibodies and form the basis for DM [14,15].